Madrigal Pharmaceuticals
MDGL
283 hedge funds and large institutions have $7.08B invested in Madrigal Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 67 funds opening new positions, 95 increasing their positions, 77 reducing their positions, and 37 closing their positions.
81% more first-time investments, than exits
New positions opened: 67 | Existing positions closed: 37
48% more capital invested
Capital invested by funds: $4.77B → $7.08B (+$2.31B)
23% more repeat investments, than reductions
Existing positions increased: 95 | Existing positions reduced: 77
11% more funds holding in top 10
Funds holding in top 10: 9 → 10 (+1)
10% more call options, than puts
Call options by funds: $354M | Put options by funds: $321M
10% more funds holding
Funds holding: 257 → 283 (+26)
0.81% more ownership
Funds ownership: 104.43% → 105.25% (+0.81%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair Investment Management
Chicago,
Illinois
|
+$105M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$45.6M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$40.7M |
| 4 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
+$36M |
| 5 |
SL
Siren LLC
Greenwich,
Connecticut
|
+$35.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$75.9M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$40.8M |
| 3 |
B
Braidwell
Stamford,
Connecticut
|
-$39M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$35.9M |
| 5 |
State Street
Boston,
Massachusetts
|
-$29.9M |
MDGL Hedge Fund Activity: Q4 2024 in Review
283 of the 7,606 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q4 2024, worth a combined $7.08B — up 48% from $4.77B a quarter earlier.
Buyers outnumbered sellers: 67 funds opened new MDGL positions and 37 closed out — a net gain of 30 holders — while 95 added to existing stakes and 77 trimmed.
The largest buyer was William Blair Investment Management, opening a new position worth an estimated $105M. The largest seller was Janus Henderson Group, cutting an estimated $75.9M.
- 283 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q4 2024, up from 257 in Q3 2024.
- Funds reported $7.08B of Madrigal Pharmaceuticals stock for Q4 2024, up 48% quarter-over-quarter.
- 67 funds opened new Madrigal Pharmaceuticals positions in Q4 2024 and 37 closed out, a net change of +30 holders.
- The largest Madrigal Pharmaceuticals buyer in Q4 2024 was William Blair Investment Management, an estimated $105M added.
- The largest Madrigal Pharmaceuticals seller in Q4 2024 was Janus Henderson Group, an estimated $75.9M sold.
Based on aggregated 13F filings for Q4 2024.